483 related articles for article (PubMed ID: 35612975)
1. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
[TBL] [Abstract][Full Text] [Related]
2. Coexistence of Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease.
Miyamori D; Tanaka M; Sato T; Endo K; Mori K; Mikami T; Hosaka I; Hanawa N; Ohnishi H; Furuhashi M
J Am Heart Assoc; 2023 Jul; 12(14):e030269. PubMed ID: 37421273
[TBL] [Abstract][Full Text] [Related]
3. Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses.
Mori K; Tanaka M; Hosaka I; Mikami T; Endo K; Hanawa N; Ohnishi H; Furuhashi M
Hypertens Res; 2023 May; 46(5):1110-1121. PubMed ID: 36717630
[TBL] [Abstract][Full Text] [Related]
4. MAFLD and risk of CKD.
Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
[TBL] [Abstract][Full Text] [Related]
5. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
Hu Q; Chen Y; Bao T; Huang Y
Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
[TBL] [Abstract][Full Text] [Related]
6. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study.
Jung CY; Koh HB; Park KH; Joo YS; Kim HW; Ahn SH; Park JT; Kim SU
Diabetes Metab; 2022 Jul; 48(4):101344. PubMed ID: 35346856
[TBL] [Abstract][Full Text] [Related]
7. The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study.
Wei S; Song J; Xie Y; Huang J; Yang J
JMIR Public Health Surveill; 2023 May; 9():e45050. PubMed ID: 37140958
[TBL] [Abstract][Full Text] [Related]
8. MAFLD and CKD: An Updated Narrative Review.
Mantovani A; Lombardi R; Cattazzo F; Zusi C; Cappelli D; Dalbeni A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806010
[TBL] [Abstract][Full Text] [Related]
9. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
11. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD.
Li Y; Wu S; Gao J; Zhang Y; Zuo Y; Tian X; Chen S; Xing A; Wang A; He Y
Am J Kidney Dis; 2024 Apr; 83(4):477-488. PubMed ID: 37838141
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China.
Wang Y; Yu Y; Zhang H; Chen C; Wan H; Chen Y; Xia F; Yu S; Wang N; Ye L; Lu Y
Front Endocrinol (Lausanne); 2022; 13():968766. PubMed ID: 36120461
[TBL] [Abstract][Full Text] [Related]
13. MAFLD and NAFLD in the prediction of incident chronic kidney disease.
Kwon SY; Park J; Park SH; Lee YB; Kim G; Hur KY; Koh J; Jee JH; Kim JH; Kang M; Jin SM
Sci Rep; 2023 Jan; 13(1):1796. PubMed ID: 36720976
[TBL] [Abstract][Full Text] [Related]
14. The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease.
Arase Y; Suzuki F; Kobayashi M; Suzuki Y; Kawamura Y; Matsumoto N; Akuta N; Kobayashi M; Sezaki H; Saito S; Hosaka T; Ikeda K; Kumada H; Ohmoto Y; Amakawa K; Tsuji H; Hsieh SD; Kato K; Tanabe M; Ogawa K; Hara S; Kobayashi T
Intern Med; 2011; 50(10):1081-7. PubMed ID: 21576832
[TBL] [Abstract][Full Text] [Related]
15. Association of metabolic dysfunction-associated fatty liver disease with kidney disease.
Wang TY; Wang RF; Bu ZY; Targher G; Byrne CD; Sun DQ; Zheng MH
Nat Rev Nephrol; 2022 Apr; 18(4):259-268. PubMed ID: 35013596
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes.
Targher G; Mantovani A; Pichiri I; Mingolla L; Cavalieri V; Mantovani W; Pancheri S; Trombetta M; Zoppini G; Chonchol M; Byrne CD; Bonora E
Diabetes Care; 2014 Jun; 37(6):1729-36. PubMed ID: 24696459
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic fatty liver disease without overlapping metabolic-associated fatty liver disease and the risk of incident type 2 diabetes.
Cho Y; Chang Y; Ryu S; Wild SH; Byrne CD
Liver Int; 2023 Nov; 43(11):2445-2454. PubMed ID: 37387519
[TBL] [Abstract][Full Text] [Related]
18. Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease.
Su W; Chen M; Xiao L; Du S; Xue L; Feng R; Ye W
Front Public Health; 2022; 10():1047794. PubMed ID: 36420005
[TBL] [Abstract][Full Text] [Related]
19. The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study.
Huh JH; Kim JY; Choi E; Kim JS; Chang Y; Sung KC
PLoS One; 2017; 12(7):e0180951. PubMed ID: 28738057
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
Moon JH; Kim W; Koo BK; Cho NH;
Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]